<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Close on heels of the U.S. Food and Drug Administration issuing restricted authorization for the Pfizer Inc. (NYSE: PFE)-BioNTech SE – ADR (NASDAQ: BNTX) COVID-19 booster vaccine dose, it is also expected to greenlight rival vaccine maker Moderna Inc.’s (NASDAQ: MRNA) half-dose mRNA vaccine as a booster shot, reported Bloomberg, citing people familiar with the matter Moderna’s COVID-19 vaccine is approved for use in adults as well as adolescents in two-dose series of 100mcg each, given 28 days apart. The FDA has also authorized an additional dose for moderately-to-severely immunocompromised people at least 28 days after the initial two-dose primary series.
...read full article on Benzinga
